Skip to main content

10.10.2017 | Onkologie | Onlineartikel

Immunostimulation as a promising approach in SCLC

Judith Moser
There is a high unmet medical need regarding extensive-disease small-cell lung cancer (SCLC) that shows poor outcomes with median OS of 9 to 11 months. First-line chemotherapy usually evokes marked responses, but responders typically experience only limited periods of disease control. Read more ...

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten